Adverum Price To Sales Ratio vs Ev To Sales Analysis

ADVM Stock

USD 10.43 0.43 4.30%

Adverum Biotechnologies financial indicator trend analysis is way more than just evaluating Adverum Biotechnologies prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Adverum Biotechnologies is a good investment. Please check the relationship between Adverum Biotechnologies Price To Sales Ratio and its Ev To Sales accounts. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Adverum Biotechnologies. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in real.

To learn how to invest in Adverum Stock, please use our How to Invest in Adverum Biotechnologies guide.

Price To Sales Ratio vs Ev To Sales

Price To Sales Ratio vs Ev To Sales Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Adverum Biotechnologies Price To Sales Ratio account and Ev To Sales. At this time, the significance of the direction appears to have totally related.

The correlation between Adverum Biotechnologies' Price To Sales Ratio and Ev To Sales is 1.0. Overlapping area represents the amount of variation of Price To Sales Ratio that can explain the historical movement of Ev To Sales in the same time period over historical financial statements of Adverum Biotechnologies, assuming nothing else is changed. The correlation between historical values of Adverum Biotechnologies' Price To Sales Ratio and Ev To Sales is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Price To Sales Ratio of Adverum Biotechnologies are associated (or correlated) with its Ev To Sales. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Ev To Sales has no effect on the direction of Price To Sales Ratio i.e., Adverum Biotechnologies' Price To Sales Ratio and Ev To Sales go up and down completely randomly.

Correlation Coefficient

1.0

Relationship Direction	Positive
Relationship Strength	Very Strong

View All Relationships

Price To Sales Ratio

Price to Sales Ratio is figured by comparing Adverum Biotechnologies stock price to its revenues. An advantage to using Price to Sales ratio is that it is based on Adverum Biotechnologies sales, a figure that is much harder to manipulate than other Adverum Biotechnologies multiples. Because sales tend to be more stable P/S ratio can be a good tool for screening cyclical companies fluctuating earnings patterns. A valuation ratio that compares a company’s stock price to its revenues, calculated by dividing the company’s market cap by its total sales or revenue over a 12-month period.

Ev To Sales

The Enterprise Value to Sales ratio, a valuation metric used to compare the value of a company, including debt and excluding cash, to its sales revenue.

Most indicators from Adverum Biotechnologies' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Adverum Biotechnologies current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Adverum Biotechnologies. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in real.

To learn how to invest in Adverum Stock, please use our How to Invest in Adverum Biotechnologies guide.As of the 4th of May 2024, Sales General And Administrative To Revenue is likely to grow to 17.94, while Selling General Administrative is likely to drop about 31.8 M.

	2021	2022	2023	2024 (projected)
Total Operating Expenses	153.6M	157.1M	121.7M	81.4M
Cost Of Revenue	4.6M	6.5M	5.6M	5.4M

Total Operating Expenses Cost Of Revenue

Adverum Biotechnologies fundamental ratios Correlations

	Total Assets	Short Long Term Debt Total	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Other Liab	Property Plant And Equipment Net	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Long Term Debt	Cash And Short Term Investments	Net Receivables	Common Stock Shares Outstanding	Non Current Liabilities Total	Other Current Assets	Other Stockholder Equity	Total Liab	Property Plant And Equipment Gross	Total Current Assets	Property Plant Equipment	Non Currrent Assets Other	Other Assets	Net Tangible Assets
Total Assets		0.63	0.26	0.74	0.94	0.18	0.65	-0.06	-0.61	0.56	0.35	0.66	-0.52	0.94	0.46	-0.19	0.6	0.64	0.82	0.65	0.61	0.94	0.31	0.12	0.43	0.84
Short Long Term Debt Total	0.63		0.68	0.84	0.38	-0.05	0.89	0.32	-0.83	0.35	0.07	0.9	-0.53	0.39	0.5	-0.33	0.93	0.6	0.8	0.93	0.92	0.41	0.71	0.58	0.84	0.33
Other Current Liab	0.26	0.68		0.69	-0.02	-0.3	0.57	0.29	-0.82	0.35	0.02	0.57	-0.23	0.01	-0.15	-0.12	0.67	0.44	0.61	0.62	0.68	0.02	0.89	0.94	0.84	0.06
Total Current Liabilities	0.74	0.84	0.69		0.55	-0.12	0.88	0.3	-0.89	0.72	0.06	0.89	-0.43	0.55	0.22	-0.41	0.84	0.83	0.95	0.91	0.84	0.56	0.72	0.5	0.76	0.47
Total Stockholder Equity	0.94	0.38	-0.02	0.55		0.32	0.42	-0.27	-0.33	0.48	0.46	0.42	-0.47	1.0	0.4	-0.03	0.31	0.49	0.66	0.42	0.33	1.0	-0.01	-0.13	0.11	0.82
Other Liab	0.18	-0.05	-0.3	-0.12	0.32		-0.31	-0.76	0.23	-0.13	0.74	-0.28	-0.23	0.35	0.04	0.45	-0.25	-0.18	-0.1	-0.21	-0.3	0.34	-0.28	-0.18	-0.32	-0.03
Property Plant And Equipment Net	0.65	0.89	0.57	0.88	0.42	-0.31		0.55	-0.8	0.47	-0.18	1.0	-0.34	0.41	0.54	-0.58	0.95	0.7	0.84	0.99	0.96	0.42	0.64	0.39	0.79	0.43
Net Debt	-0.06	0.32	0.29	0.3	-0.27	-0.76	0.55		-0.4	0.15	-0.91	0.54	0.31	-0.3	0.21	-0.58	0.54	0.24	0.25	0.48	0.56	-0.28	0.41	0.17	0.49	0.03
Retained Earnings	-0.61	-0.83	-0.82	-0.89	-0.33	0.23	-0.8	-0.4		-0.57	0.03	-0.81	0.34	-0.34	-0.2	0.36	-0.88	-0.73	-0.89	-0.84	-0.88	-0.36	-0.91	-0.68	-0.94	-0.46
Accounts Payable	0.56	0.35	0.35	0.72	0.48	-0.13	0.47	0.15	-0.57		0.03	0.47	-0.32	0.48	-0.08	-0.28	0.38	0.9	0.65	0.47	0.36	0.49	0.37	0.12	0.34	0.36
Cash	0.35	0.07	0.02	0.06	0.46	0.74	-0.18	-0.91	0.03	0.03		-0.17	-0.53	0.49	-0.03	0.42	-0.14	0.03	0.1	-0.1	-0.17	0.48	-0.08	0.09	-0.12	0.15
Non Current Assets Total	0.66	0.9	0.57	0.89	0.42	-0.28	1.0	0.54	-0.81	0.47	-0.17		-0.34	0.41	0.54	-0.56	0.96	0.7	0.85	0.99	0.96	0.43	0.65	0.4	0.79	0.43
Long Term Debt	-0.52	-0.53	-0.23	-0.43	-0.47	-0.23	-0.34	0.31	0.34	-0.32	-0.53	-0.34		-0.48	-0.2	0.23	-0.34	-0.37	-0.4	-0.37	-0.32	-0.48	-0.27	-0.21	-0.31	-0.35
Cash And Short Term Investments	0.94	0.39	0.01	0.55	1.0	0.35	0.41	-0.3	-0.34	0.48	0.49	0.41	-0.48		0.38	-0.01	0.31	0.48	0.66	0.41	0.33	1.0	0.01	-0.1	0.12	0.82
Net Receivables	0.46	0.5	-0.15	0.22	0.4	0.04	0.54	0.21	-0.2	-0.08	-0.03	0.54	-0.2	0.38		-0.19	0.52	0.25	0.33	0.51	0.5	0.39	-0.05	-0.16	0.27	0.37
Common Stock Shares Outstanding	-0.19	-0.33	-0.12	-0.41	-0.03	0.45	-0.58	-0.58	0.36	-0.28	0.42	-0.56	0.23	-0.01	-0.19		-0.53	-0.35	-0.3	-0.52	-0.53	-0.02	-0.43	0.07	-0.41	-0.25
Non Current Liabilities Total	0.6	0.93	0.67	0.84	0.31	-0.25	0.95	0.54	-0.88	0.38	-0.14	0.96	-0.34	0.31	0.52	-0.53		0.63	0.8	0.96	0.99	0.32	0.78	0.53	0.91	0.39
Other Current Assets	0.64	0.6	0.44	0.83	0.49	-0.18	0.7	0.24	-0.73	0.9	0.03	0.7	-0.37	0.48	0.25	-0.35	0.63		0.8	0.7	0.6	0.5	0.5	0.23	0.57	0.38
Other Stockholder Equity	0.82	0.8	0.61	0.95	0.66	-0.1	0.84	0.25	-0.89	0.65	0.1	0.85	-0.4	0.66	0.33	-0.3	0.8	0.8		0.87	0.81	0.67	0.66	0.43	0.73	0.65
Total Liab	0.65	0.93	0.62	0.91	0.42	-0.21	0.99	0.48	-0.84	0.47	-0.1	0.99	-0.37	0.41	0.51	-0.52	0.96	0.7	0.87		0.96	0.43	0.69	0.47	0.82	0.4
Property Plant And Equipment Gross	0.61	0.92	0.68	0.84	0.33	-0.3	0.96	0.56	-0.88	0.36	-0.17	0.96	-0.32	0.33	0.5	-0.53	0.99	0.6	0.81	0.96		0.34	0.78	0.54	0.9	0.43
Total Current Assets	0.94	0.41	0.02	0.56	1.0	0.34	0.42	-0.28	-0.36	0.49	0.48	0.43	-0.48	1.0	0.39	-0.02	0.32	0.5	0.67	0.43	0.34		0.03	-0.09	0.13	0.82
Property Plant Equipment	0.31	0.71	0.89	0.72	-0.01	-0.28	0.64	0.41	-0.91	0.37	-0.08	0.65	-0.27	0.01	-0.05	-0.43	0.78	0.5	0.66	0.69	0.78	0.03		0.78	0.94	0.2
Non Currrent Assets Other	0.12	0.58	0.94	0.5	-0.13	-0.18	0.39	0.17	-0.68	0.12	0.09	0.4	-0.21	-0.1	-0.16	0.07	0.53	0.23	0.43	0.47	0.54	-0.09	0.78		0.77	-0.08
Other Assets	0.43	0.84	0.84	0.76	0.11	-0.32	0.79	0.49	-0.94	0.34	-0.12	0.79	-0.31	0.12	0.27	-0.41	0.91	0.57	0.73	0.82	0.9	0.13	0.94	0.77		0.29
Net Tangible Assets	0.84	0.33	0.06	0.47	0.82	-0.03	0.43	0.03	-0.46	0.36	0.15	0.43	-0.35	0.82	0.37	-0.25	0.39	0.38	0.65	0.4	0.43	0.82	0.2	-0.08	0.29

Click cells to compare fundamentals

Adverum Biotechnologies Account Relationship Matchups

Adverum Biotechnologies fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	222.7M	482.6M	439.7M	308.4M	173.0M	247.9M
Other Current Liab	2.6M	1.3M	2.0M	16.8M	12.5M	13.1M
Total Current Liabilities	19.4M	20.9M	21.3M	32.2M	24.9M	15.0M
Total Stockholder Equity	175.0M	434.3M	316.2M	181.5M	83.5M	79.3M
Other Liab	1.4M	48K	1.1M	1.0M	942.3K	895.2K
Property Plant And Equipment Net	45.8M	47.1M	119.1M	113.9M	67.0M	37.4M
Net Debt	(33.6M)	(31.7M)	68.8M	38.4M	36K	37.8K
Retained Earnings	(385.0M)	(502.5M)	(648.1M)	(802.6M)	(919.8M)	(873.8M)
Accounts Payable	4.1M	2.8M	1.4M	2.2M	1.9M	1.9M
Cash	65.9M	62.4M	34.2M	68.4M	75M	78.2M
Non Current Assets Total	46.9M	48.1M	122.6M	117.8M	70.2M	39.7M
Cash And Short Term Investments	166.0M	429.7M	305.2M	185.6M	96.5M	91.7M
Common Stock Shares Outstanding	6.4M	8.5M	9.8M	9.9M	10.1M	18.4M
Liabilities And Stockholders Equity	222.7M	482.6M	439.7M	308.4M	173.0M	247.9M
Non Current Liabilities Total	28.4M	27.3M	102.2M	94.6M	64.6M	67.9M
Other Current Assets	9.8M	4.7M	6.2M	5.0M	6.2M	4.0M
Other Stockholder Equity	560.7M	937.1M	965.0M	985.7M	1.0B	567.3M
Total Liab	47.8M	48.2M	123.5M	126.9M	89.5M	46.9M
Property Plant And Equipment Gross	24.9M	47.1M	132.2M	130.9M	81.5M	85.6M
Total Current Assets	175.9M	434.4M	317.1M	190.6M	102.8M	97.6M
Accumulated Other Comprehensive Income	(725K)	(261K)	(714K)	(1.5M)	(473K)	(496.7K)
Property Plant Equipment	24.9M	27.7M	33.1M	113.9M	130.9M	137.5M
Non Currrent Assets Other	11K	29K	250K	1.4M	1.2M	1.3M
Other Assets	1.0M	1.0M	3.5M	3.9M	4.5M	4.7M
Net Tangible Assets	175.0M	434.3M	316.2M	181.5M	208.7M	256.7M
Common Stock Total Equity	5K	6K	7K	10K	11.5K	6.5K
Retained Earnings Total Equity	(320.5M)	(385.0M)	(502.5M)	(648.1M)	(583.3M)	(554.1M)
Short Term Investments	100.1M	367.3M	271.0M	117.2M	21.5M	20.4M
Capital Surpluse	522.5M	560.7M	937.1M	965.0M	1.1B	599.6M
Short Term Debt	4.0M	4.5M	1.9M	13.2M	10.4M	6.1M
Common Stock	5K	6K	7K	10K	11.5K	7.4K
Non Current Liabilities Other	28.4M	27.3M	102.2M	1.0M	1.2M	1.1M
Net Invested Capital	175.0M	434.3M	316.2M	181.5M	83.5M	79.3M
Net Working Capital	156.5M	413.6M	295.8M	158.3M	77.9M	74.0M

Pair Trading with Adverum Biotechnologies

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Adverum Biotechnologies position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Adverum Biotechnologies will appreciate offsetting losses from the drop in the long position's value.

Moving together with Adverum Stock

0.72

VRAX

Virax Biolabs Group Fiscal Year End 12th of June 2024

Pair Corr

Moving against Adverum Stock

0.6	INDP	Indaptus Therapeutics Financial Report 9th of May 2024	Pair Corr
0.58	LIXT	Lixte Biotechnology Earnings Call This Week	Pair Corr
0.5	GBIO	Generation BioCo Financial Report 8th of May 2024	Pair Corr
0.49	ELVN	Enliven Therapeutics Trending	Pair Corr

The ability to find closely correlated positions to Adverum Biotechnologies could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Adverum Biotechnologies when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Adverum Biotechnologies - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Adverum Biotechnologies to buy it.

The correlation of Adverum Biotechnologies is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Adverum Biotechnologies moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Adverum Biotechnologies moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.

Correlation analysis and pair trading evaluation for Adverum Biotechnologies can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.

Pair Correlation Correlation Matching

When determining whether Adverum Biotechnologies is a strong investment it is important to analyze Adverum Biotechnologies' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Adverum Biotechnologies' future performance. For an informed investment choice regarding Adverum Stock, refer to the following important reports:

How To Invest In Adverum

Details

Is Adverum Stock a good investment?

Details

What is Adverum Biotechnologies' Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Adverum Biotechnologies. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in real.

To learn how to invest in Adverum Stock, please use our How to Invest in Adverum Biotechnologies guide.

You can also try the Crypto Correlations module to use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins.

Complementary Tools for Adverum Stock analysis

When running Adverum Biotechnologies' price analysis, check to measure Adverum Biotechnologies' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Adverum Biotechnologies is operating at the current time. Most of Adverum Biotechnologies' value examination focuses on studying past and present price action to predict the probability of Adverum Biotechnologies' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Adverum Biotechnologies' price. Additionally, you may evaluate how the addition of Adverum Biotechnologies to your portfolios can decrease your overall portfolio volatility.

	Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators
	Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities
	Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges
	Commodity Channel Use Commodity Channel Index to analyze current equity momentum
	Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing
	Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios
	Transaction History View history of all your transactions and understand their impact on performance
	Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk
	Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum
	FinTech Suite Use AI to screen and filter profitable investment opportunities

Is Adverum Biotechnologies' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Adverum Biotechnologies. If investors know Adverum will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Adverum Biotechnologies listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(11.60)

Revenue Per Share

0.357

Quarterly Revenue Growth

(0.70)

Return On Assets

(0.32)

Return On Equity

(0.88)

The market value of Adverum Biotechnologies is measured differently than its book value, which is the value of Adverum that is recorded on the company's balance sheet. Investors also form their own opinion of Adverum Biotechnologies' value that differs from its market value or its book value, called intrinsic value, which is Adverum Biotechnologies' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Adverum Biotechnologies' market value can be influenced by many factors that don't directly affect Adverum Biotechnologies' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Adverum Biotechnologies' value and its price as these two are different measures arrived at by different means. Investors typically determine if Adverum Biotechnologies is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Adverum Biotechnologies' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Adverum Price To Sales Ratio vs Ev To Sales Analysis

Price To Sales Ratio vs Ev To Sales

Price To Sales Ratio vs Ev To Sales Correlation Analysis

Correlation Coefficient

Price To Sales Ratio

Ev To Sales

Adverum Biotechnologies fundamental ratios Correlations

Adverum Biotechnologies Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Adverum Biotechnologies fundamental ratios Accounts

Pair Trading with Adverum Biotechnologies

Moving together with Adverum Stock

Moving against Adverum Stock

Complementary Tools for Adverum Stock analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Cash And Short Term Investments	+ 1.0	Total Stockholder Equity
Total Current Assets	+ 1.0	Total Stockholder Equity
Non Current Assets Total	+ 1.0	Property Plant And Equipment Net
Total Current Assets	+ 1.0	Cash And Short Term Investments
Total Liab	+ 0.99	Property Plant And Equipment Net
Total Liab	+ 0.99	Non Current Assets Total

Other Assets	- 0.94	Retained Earnings
Property Plant Equipment	- 0.91	Retained Earnings
Cash	- 0.91	Net Debt
Other Stockholder Equity	- 0.89	Retained Earnings
Retained Earnings	- 0.89	Total Current Liabilities
Property Plant And Equipment Gross	- 0.88	Retained Earnings